Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel

List of participants:

1. Dr Marylyn Addo, Professor of Emerging Infections, Universitätsklinikum Hamburg-Eppendorf, German Center of Infectious Diseases Research (DZIF), Hamburg, Germany
2. Dr Clement Adebamowo, Chairman, National Health Research Ethics Committee of Nigeria, Federal Ministry of Health, Abuja, Nigeria
3. Dr Selidji Agnandji, Franceville, Gabon
5. Dr Sylvain Baize, Biology of Viral Emerging Infections, Institut Pasteur, Paris, France
6. Dr Younoussa Ballo, Secrétaire general, Ministère de la Santé, Conakry, Guinea
7. Dr Ripley Ballou, GlaxoSmithKline Biologicals SA, Rixensart, Belgium
8. Ms Helia Baradarani, Tekmira’s Manager of Medical Countermeasure Business Development, Vancouver, Canada
9. Dr Jarbas Barbosa, Vice Minister, Ministry of Health, Brasilia, Brazil
10. Dr Jesus Barral-Guerin, Senior Manager, Vaccine Centre, Supply Division, UNICEF, Copenhagen, Denmark
11. Dr Daniel Bausch, Associate Professor, Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, New Orleans, USA
12. Dr Sina Bavari, CIV US Army Medcom USA MRIID, USA
13. Dr Stephan Becker, Direktor, Institut für Virologie, Marburg, Germany
14. Dr Laetitia Bigger, Senior Manager, Vaccines Policy, IFPMA, Geneva, Switzerland
15. Dr Fred Binka, Vice Chancellor, University of Health and Allied Sciences, Ho, Ghana
16. Dr Francisco Blanco, Chief of Medicines & Nutrition, Supply Division, UNICEF, Copenhagen, Denmark
17. Dr Luciana Borio, Director, Office of Counterterrorism and Emerging Threats (OCET) in the Office of the Chief Scientist, U.S. Food and Drug Administration (FDA), Rockville, USA
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

18. Dr Abdullah Brooks, Centre for Health and Population Research, Dhaka, Bangladesh

19. Dr Philippe Calain, Unité de Recherche sur les Enjeux et Pratiques humanitaires (UREPH), Médecins sans Frontières, Geneva, Switzerland

20. Dr Michael Callahan, Command Physician, Rescue Medicine/Réseau Médical Patient Filovirus, Kinsasha, Harvard Medical School, Massachusetts General Hospital, Boston, USA

21. Dr Benoit Callendret, Crucell, Leiden, Netherlands

22. Dr Iris Chang, Hong Kong Academy of Pharmacy, Hong Kong, People’s Republic of China

23. Dr George Christopher, Chief Medical Officer, Joint Project Manager – Medical Countermeasure Systems, Department of Defense, Rockville, USA

24. Dr Supamit Chunsuttiwat, Senior Medical Officer, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand

25. Dr Jacob Cohn, Bavarian Nordic A/S, Kvistgaard, Denmark

26. Dr Christoph Conrad, Paul-Ehrlich-Institut, Langen, Germany

27. Mr Stephan Cook, Vice President, Vaccine Global Regulatory Affairs, Vaccine Value & Health Science, GlaxoSmithKline Biologicals SA, Rixensart, Belgium

28. Dr Marion Danis, Head, Section on Ethics and Health Policy, NIH, Bethesda, USA

29. Prof Jean-François Delfraissy, Director of Agence nationale de Recherche (ANRS), Paris, France

30. Dr Martin de Smet, Médecins sans Frontières, Brussels, Belgium

31. Dr Antal Tal Dia, Chairman, National Immunization Technical Advisory Group (NITAG) Senegal, Dakar, Senegal

32. Dr Alpha Amadou Diallo, Rapporteur du Comité national d’Ethique et de Recherche en Santé, Conakry, Guinea

33. Prof Ousmane Doumbia, Secrétaire general, Ministère de la Santé et del’Hygiène publique, Bamako, Mali

34. Dr Karifa Douno, Chef, Division Etablissements biopharmaceutiques, Ministère de la Santé, Conakry, Guinea

35. Dr Mattias Egger, Professor of Epidemiology and Public Health, University of Bern, Bern, Switzerland
Consultation on potential Ebola therapies and vaccines
4–5 September 2014
Geneva, Starling Hotel, Room Montana

36. Dr Lindsay Elmgren, Director, Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada

37. Dr Carol Epstein, MediVector, Inc. Fujifilm Pharmaceuticals USA, Boston, USA

38. Dr Jeremy Farrar, Director, Wellcome Trust, London, United Kingdom of Great Britain & Northern Ireland

39. Dr Patricia Fast, International AIDS Vaccine Initiative, New York, USA

40. Dr Eleanor Fish, University of Toronto, Toronto, Canada

41. Prof Fu Gao, Deputy Director General for sciences, China CDC, Beijing, China

42. Dr Jennifer Gibson, Director, Joint Centre for Bioethics, Director, World Health Organization Collaborating Centre for Bioethics, Associate Professor, Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, Canada

43. Dr Dennis Giesing, Vice President, Preclinical Research, MediVector, Inc. Fujifilm Pharmaceuticals USA, Boston, USA

44. Dr Jesse Goodman, George Town University, Washington, USA

45. Dr Barney Graham, Vaccine Research Centre, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA

46. Dr Nyankoye Haba, National Blood Service, Conakry, Guinea

47. Dr Fred Hayden, University of Virginia/WHO consultant, Charlottesville, USA

48. Dr Lisa Hensley, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA

49. Dr Elizabeth Higgs, Global Health Science Advisor, Office of the Director, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA

50. Dr David Hone, Chief, Vaccine Branch, Research and Development Directorate (J9), Defense Threat Reduction Agency (DTRA), Department of Defense, Fort Belvoir, USA

51. Dr Peter Horby, University of Oxford, Oxford, United Kingdom of Great Britain & Northern Ireland

52. Dr Angela Huttner, Infection Control Programme, University Hospitals of Geneva, Switzerland

53. Dr Ryuichi Ida, Member of the Expert Panel on Bioethics (National Bioethics Committee), Kyoto, Japan
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

54. Dr Giuseppe Ippolito, Scientific Director, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy

55. Dr Ambrose Isah, GACVS representative, Benin City, Nigeria

56. Dr Aikichi Iwamoto, The Institute of Medical Sciences, Research Center for Asian Infectious Diseases, Japan

57. Dr Amandua Jacinto, Commissioner Clinical Services, Ministry of Health and Social Welfare, Kampala, Uganda


59. Dr Franca Jones, Medical Director, Chemical and Biological Defense Program, Office of the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs OASD(NCB/CB), Rockville, USA


61. Ms Sadia Kaenzig, Manager, Communications, IFPMA, Geneva Switzerland

62. Dr Robinah Kaitiritimba, Uganda National Health Consumers’ Organisation (UNHCO), Kampala Uganda

63. Dr Samuel Kargbo, Director, Reproductive and Child Health, Ministry of Health and Sanitation, Freetown, Sierra Leone

64. Dr Christopher Karp, Deputy Director, Discovery and Translational Sciences, Bill & Melinda Gates Foundation, Seattle, USA

65. Dr Francis N. Kateh, Medical Director/CEO, Jackson F. Doe Memorial Regional Referral Hospital, Tappita City, Lower Nimba County, Liberia

66. Dr Steve Kern, Deputy Director, Integrated Development, Bill & Melinda Gates Foundation, Seattle, USA

67. Dr Nadia Khelef, Institut Pasteur, Paris, France

68. Dr Hiroshi Kitaguchi, General Manager, Business Development Department, Toyama Chemical Co., Ltd., Tokyo, Japan

69. Dr Gary Kobinger, Public Health Agency of Canada, Vancouver, Canada

70. Dr Daniel Koch, Federal Office of Public Health, Bern, Switzerland
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

71. Dr Mandy Kader Kondé, Président de la Commission Recherche Ebola, Conakry, Guinea
72. Dr Bocar Kouyate, Office of the Minister of Health, Ouagadougou, Burkina Faso
73. Dr Sanjeev Krishna, London, United Kingdom of Great Britain & Northern Ireland
74. Dr Michael Kurilla, Director, Office of BioDefense, Research Resources, and Translational Research, Associate Director for BioDefense Product Development, NIAID, NIH, Rockville, USA
75. Dr Randall Lanier, Executive Director of Biology, Chimerix Inc., Durham, USA
76. Dr James Lawler, Director, ACESO/Clinical Research Partner in Uganda, Kampala, Uganda
77. Dr Robert Lenk, EVP and CSO, MediVector, Boston, USA
78. Dr Bertand Lepine, FabEntech, Lyon, France
79. Dr Mike Levine, Director, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA
80. Dr Nicole Lurie, Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services, Washington, USA
81. Dr Ian MacLachlan, Executive Vice President and Chief Technical Officer, Tekmira Pharmaceuticals Corp., Vancouver, Canada
82. Dr Alan Magill, Director, Malaria, Bill & Melinda Gates Foundation, Seattle, USA
83. Prof Denis Malvy, Professor in Infectious Diseases, Bordeaux, France
84. Dr Brian K. Martin, Director, Infectious Disease Division, BioProtection Systems, a wholly-owned subsidiary of NewLink Genetics, Ames, USA
85. Dr Jacques-François Martin, Fab Entech, Lyon, France
86. Dr Eric Mast, Deputy Director Science and Research, Center for Disease Control and Prevention, Atlanta, USA
87. Dr Gisele Mbuyi, Department of Disease Control, Ministry of Health and Population, Brazzaville, Congo
88. Dr Jeffrey N. Meshulam, President, Profectus BioSciences, Inc., Baltimore, USA
89. Dr Mike Miller, Executive Director, Early Discovery, Merck Research Laboratories Division, Whitehouse Station, USA
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

90. Dr Philip Minor, National Institute for Biological Standards and Control, United Kingdom of Great Britain & Northern Ireland

91. Ms Viviana Munoz, Manager of the Innovation and Access to Knowledge Programme at the South Centre, Geneva, Switzerland

92. Dr Abdulalami Nasidi, Nigeria Center for Disease Control, Abuja, Nigeria

93. Dr Helen Byomire Ndagije, Head of the Drug Information Department in the Ugandan National Drug Authority (NDA), Kampala, Uganda

94. Dr Mariane Ngoulla, Special Adviser on Health to ECOWAS President, Abuja, Nigeria

95. Prof Cheikh Niang, Anthropologist, Cheikh Anta Diop University, Dakar, Senegal

96. Dr Sérgio Nishioka, Clinical Expert, Brasilia, Brazil

97. Dr Dieudonné Nkoghe, Ministère de la Santé publique, Centre international de Recherches médicales, Franceville, Gabon

98. Dr Jeanne Novak, Principal, CBR International, Mapp Biopharmaceutical, Inc., San Diego, USA

99. Dr Jean-Marc Olive, Scientific Researcher, French National Centre for Scientific Research, Paris, France

100. Mr Tomoko Onoda, First Secretary, Permanent Mission of Japan, Geneva, Switzerland

101. Dr Paul Orhii, Director General, National Agency for Food and Drug Administration and Control, Abuja, Nigeria

102. Prof Dominique Peyramond , Hôpital de la Croix Rousse, Lyon, France

103. Dr Olga Popova, Crucell, Leiden, Netherlands

104. Dr W. Jay Ramsey, Clinical and Regulatory Compliance Officer, NewLink Genetics, Ames, USA

105. Dr Robin Robinson, Director, Biomedical Advanced Research & Development Authority, US Department of Health and Human Services, Washington, USA

106. Dr Francois Roman, GlaxoSmithKline Biologicals SA, Rixensart, Belgium

107. Dr Robin Ruepp, EMA , London, United Kingdom of Great Britain & Northern Ireland

108. Dr Leonard Ruiz, International Medical Foundation, Rochester, USA
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

109. Dr Amadou Sall, Institut Pasteur, Dakar, Senegal

110. Dr Mohamed Samai, Deputy Director for Research, Ministry of Health and Sanitation, Freetown, Sierra Leone

111. Dr Sangeeta Sashikant, Third World Network, London, United Kingdom of Great Britain & Northern Ireland

112. Dr Manuel Schibler, Hôpitaux universitaires de Genève, Geneva, Switzerland

113. Dr Michael Schmoyer, Director, Office of Pandemics and Emerging Threats, Office of Global Affairs—International Health Action for a Healthier US, U.S. Department of Health and Human Services, Washington, USA

114. Dr Jürg Seiler, toxicologist/assessor, Switzerland

115. Dr Michael Selgelid, Director of the Centre for Human Bioethics, Monash University, Canberra, Australia

116. Dr Caroline Semaille, Directeur des Médicaments Anti-infectieux, Hépato-gastroentérologie, Dermatologie, et Maladies métaboliques rares, Agence nationale de Sécurité des Medicaments, Saint-Denis, France

117. Dr William P. Sheridan, Senior Vice President and Chief Medical Officer, BioCryst Pharmaceuticals Inc., Durham, USA

118. Dr Neil T. Shahrestani, New York, USA

119. Prof Peter Smith, Professor of Tropical Epidemiology, London School of Tropical Medicine and Hygiene, London, United Kingdom of Great Britain & Northern Ireland

120. Dr Kabiné Souaré, Directeur national de la Pharmacie et des Laboratoires, Ministère de la Santé, Conakry, Guinea

121. Prof Samba Sow, Director General, Center for Vaccine Development-Mali, CNAM, Bamako, Mali

122. Dr Christina Spiropolou, Center for Disease Control and Prevention, Atlanta, USA

123. Dr Armand Sprecher, Médecins sans Frontières, Brussels, Belgium

124. Dr Vernon Stringer, Health Canada, Ottawa, Canada

125. Dr Adrian Sullivan, Information Management Specialist, Supply Division, UNICEF, Copenhagen, Denmark
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

126. Dr Theresa Tam, Branch Head, Health Security Infrastructure Branch, Public Health Agency of Canada, Ottawa, Canada

127. Dr Oyewale Tomori, Professor of Virology, Redeemer’s University, Redemption City, Nigeria

128. Dr Aissatou Toure, Head of Immunology Department, Institut Pasteur, Dakar, Senegal

129. Prof Mamadou Soucoulo Traore, Directeur général, Institut national de Recherche en Santé publique, Bamako, Mali

130. Dr Jeffrey Ulmer, Global Head, External Research, Novartis Vaccines and Diagnostics, Inc., Cambridge, USA

131. Dr Ross Upshur, Director, Joint Centre for Bioethics, University of Toronto, Toronto, Canada

132. Mr Laurent Vacher, Responsable R&D et Business Development, Fab Entech, Lyon, France

133. Dr Francisca Valdivieso, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile

134. Dr Johan van Griensven, Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium

135. Dr Johan van Hoof, Crucell, Leiden, Netherlands

136. Dr Ariane Volkman, Ebola vaccine program, Bavarian Nordic A/S, Kvistgaard, Denmark

137. Dr Jay Wang, Program Manager, Emerging Infectious Diseases Therapeutics, Joint Project Manager – Medical Countermeasure Systems, Department of Defense, Rockville, USA

138. Dr Linghang Wang, Beijing Ditan Hospital, Beijing, China

139. Dr John Whitehead, Lancaster, United Kingdom of Great Britain & Northern Ireland

140. Dr Christopher Whitty, Director Research & Evidence and Chief Scientific Adviser, Department for International Development, London, United Kingdom of Great Britain & Northern Ireland

141. Dr Michael Wong, Sarepta Therapeutics, Sarepta, USA

142. Dr Tom Wong, Director, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Canada

143. Dr Kacey Wulff, Special Assistant to the Assistant Secretary of Preparedness and Response, US Department of Health and Human Services, Washington, USA

144. Dr Margarita Xydia-Charmanta, Manager, Vaccines Policy, IFPMA, Geneva, Switzerland
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

145. Dr Koichi Yamada, FUJIFILM Corporation, Pharmaceutical Products Division, Japan
146. Dr Larry Zeitlin, President, Mapp Biopharmaceutical, Inc, San Diego, USA

WHO Secretariat

147. Dr Saxena Aaruni, Intern, Pandemic and Epidemic Diseases, HSE, Geneva, Switzerland
148. Dr Dicky Akanmori, Technical Officer, AF/RIN - Routine Immunization and New Vaccines, WHO AFRO, Brazzaville, Congo
149. Dr Anarfi Asamoa-Baah, Deputy Director-General, Geneva, Switzerland
150. Dr Bruce Aylward, Assistant Director-General, Polio, Emergencies and Country Collaboration (PEC), Geneva, Switzerland
151. Mr Christopher Bailey, Coordinator, Online Communications, DCO, Geneva, Switzerland
152. Dr Marie Charlotte Bouesseau, Service Delivery and Safety, HIS, Geneva, Switzerland
153. Dr David Brett-Major, Global Preparedness, Surveillance and Response, HSE, Geneva, Switzerland
154. Dr Sylvie Briand, Director, Pandemic and Epidemic Diseases, HSE, Geneva, Switzerland
155. Dr Margaret Chan, Director-General, Geneva, Switzerland
156. Mr Alejandro Costa, Scientist, Control of Epidemic Diseases, HSE, Geneva, Switzerland
157. Dr Caroline Marie Cross, Director, Staff Health & Wellbeing Services, Geneva, Switzerland
158. Dr Philippe Duclos, Immunization, Vaccines and Biologicals, FWC, Geneva, Switzerland
159. Ms Fadela Chaib, Communications Officer, DCO, Geneva, Switzerland
160. Mr David Fitzsimons, Meeting Rapporteur, Prévessin, France
161. Dr Thomas Fletcher, Infection Control and Publications, HSE, Geneva, Switzerland
162. Dr Martin Friede, Scientist, Essential Medicines and Health Products, HIS, Geneva, Switzerland
163. Dr Gaya Gamhewage, Coordinator, Communication Capacity Building, DCO, Geneva Switzerland
164. Mr Theo Grace, Technical Officer, Essential Medicines and Health Products, HIS, Geneva, Switzerland
165. Ms Marisol Guraiib, Technical Officer, Global Health Ethics, HIS, Geneva, Switzerland
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

166. Ms Celine Gurry, Global Preparedness, Surveillance and Response, HSE, Geneva, Switzerland

167. Dr Margaret Harris, DCO, Geneva, Switzerland

168. Dr Ana Maria Henao Restrepo, Technical Officer, Immunization, Vaccines and Biologicals, FWC, Geneva, Switzerland

169. Dr Alireza Khadem Broojerdi, Scientist, Regulatory Systems Strengthening, HIS, Geneva, Switzerland

170. Dr Marie-Paule Kieny, Assistant Director General, Health Systems and Innovation (HIS), Geneva Switzerland

171. Dr Rüdiger Krech, Director, Office of the Assistant Director-General, HIS, Geneva, Switzerland

172. Dr Annette Christiane Kuesel, Scientist, Intervention and Implementation research, HTM, Geneva, Switzerland

173. Mr Olivier Christian Lapujade, WHO Prequalification, Essential Medicines and Health Products, HIS, Geneva, Switzerland

174. Dr André Loua, Regional Adviser, Blood Safety, Laboratories and Health Technology, WHO AFRO, Brazzaville, Congo

175. Dr Nicola Magrini, Scientist, Essential Medicines and Health Products, HIS, Geneva, Switzerland

176. Dr Dermot Maher, Coordinator, TDR, HTM, Geneva, Switzerland

177. Mr Issa Matta, Commercial and Contractual Matters, DGO, Geneva, Switzerland

178. Ms Anne Mazur, Principal Legal Officer, Commercial and Contractual Matters, DGO, Geneva, Switzerland

179. Dr Andrew Meek, WHO Prequalification, Essential Medicines and Health Products, HIS, Geneva, Switzerland

180. Ms Lisa Menning, Technical Officer, Immunization, Vaccines and Biologicals, FCW, Geneva, Switzerland

181. Dr Vasee Moorthy, Technical Officer, Immunization, Vaccines and Biologicals, FCW, Geneva, Switzerland

182. Dr Ana Maria Padilla, Essential Medicines and Health Products, HIS, Geneva, Switzerland

183. Dr Shanthi Pal, Group Lead, Medicines Safety, Safety & Vigilance, Geneva, Switzerland
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel, Room Montana

184. Mr James Pfitzer, Technical Officer, Essential Medicines and Health Products, HIS, Geneva, Switzerland
185. Dr Analia Porras, Medicine Unit, PAHO/AMRO, Washington DC, USA
186. Dr Andreas Reis, Technical Officer, Global Health Ethics, HIS, Geneva, Switzerland
188. Dr Cathy Roth, Advisor, HSE, Geneva, Switzerland
189. Dr Carla Saenz, Bioethics advisor, PAHO/AMRO, Washington, USA
190. Dr Abha Saxena, Coordinator, Global Health Ethics, HIS, Geneva, Switzerland
191. Dr Nahoko Shindo, Medical Officer, Infection Control and Publications, HSE, Geneva Switzerland
192. Ms Erin Sparrow, Technical Officer, Essential Medicines and Health Products, HIS, Geneva, Switzerland
193. Mr Ludy Suryantoro, External Relations Officer, HSE, Geneva, Switzerland
194. Dr Kirsten Vannice, Technical Officer, Immunization, Vaccines and Biologicals, FCW, Geneva, Switzerland
195. Dr David Wood, Coordination, Technologies Standards and Norms, HIS, Geneva, Switzerland
196. Dr Wondiyfraw Worku, WHO Prequalification, Essential Medicines and Health Products, HIS, Geneva, Switzerland
197. Dr Patrick Zuber, Medical Officer, Safety and Vigilance, HIS, Geneva, Switzerland